Latest treatment for lower urinary tract dysfunction: Therapeutic agents and mechanism of action

International Journal of Urology

Volumn 20, Issue 1, 2013, Pages 28-39

  Yamaguchi, Osamu ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

1 adrenoceptor antagonists; 3 adrenoceptor agonists; 5 reductase inhibitors; Antimuscarinics; Lower urinary tract symptoms; Phosphodiesterase inhibitors

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BLR 37344; DARIFENACIN; DOBUTAMINE; DOXAZOSIN; DUTASTERIDE; FESOTERODINE; FINASTERIDE; IMIDAFENACIN; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PHOSPHODIESTERASE V INHIBITOR; PROCATEROL; PROPIVERINE; SOLIFENACIN; SR 58894A; TAMSULOSIN; TOLTERODINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; BLADDER CAPACITY; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; ISCHEMIA; LOWER URINARY TRACT SYMPTOM; MUSCLE RELAXATION; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; URINARY URGENCY; URINE RETENTION; UROTHELIUM;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE INHIBITORS; URINARY BLADDER, OVERACTIVE;

EID: 84871934949     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12008     Document Type: Review

References (128)

1. Abrams P, Cardozo L, Fall M etal. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 167-178.
2. Chapple CR, Artibani W, Cardozo LD etal. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005; 95: 335-340.
3. Irwin DE, Milsom I, Hunskaar S etal. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 2006; 50: 1306-1314; discussion 1314-15.
4. Yamaguchi O, Marui E, Kakizaki H etal. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007; 100: 579-587.
5. Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003; 92: 741-747.
6. Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int. J. Urol. 2008; 15: 986-991.
7. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004; 3: 46-53.
8. Andersson KE. Bladder activation: afferent mechanisms. Urology 2002; 59: 43-50.
9. Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes - a possible sensory mechanism? J. Physiol. 1997; 505 (Pt 2): 503-511.
10. Maggi CA. Prostanoids as local modulators of reflex micturition. Pharmacol. Res. 1992; 25: 13-20.
11. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol. Rev. 1993; 45: 253-308.
12. Birder LA, Apodaca G, De Groat WC, Kanai AJ. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am. J. Physiol. 1998; 275: F226-229.
13. Pandita RK, Mizusawa H, Andersson KE. Intravesical oxyhemoglobin initiates bladder overactivity in conscious, normal rats. J. Urol. 2000; 164: 545-550.
14. Wiseman OJ, Fowler CJ, Landon DN. The role of the human bladder lamina propria myofibroblast. BJU Int. 2003; 91: 89-93.
15. Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int. 2002; 90: 118-129.
16. Fry CH, Sui GP, Kanai AJ, Wu C. The function of suburothelial myofibroblasts in the bladder. Neurourol. Urodyn. 2007; 26: 914-919.
17. Yoshida M, Inadome A, Maeda Y etal. Non-neuronal cholinergic system in human bladder urothelium. Urology 2006; 67: 425-430.
18. Lips KS, Wunsch J, Zarghooni S etal. Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur. Urol. 2007; 51: 1042-1053.
19. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br. J. Pharmacol. 2005; 144: 1089-1099.
20. Tyagi S, Tyagi P, Van-le S, Yoshimura N, Chancellor MB, de Miguel F. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J. Urol. 2006; 176: 1673-1678.
21. Bschleipfer T, Schukowski K, Weidner W etal. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007; 80: 2303-2307.
22. Zarghooni S, Wunsch J, Bodenbenner M etal. Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci. 2007; 80: 2308-2313.
23. Kullmann FA, Artim D, Beckel J, Barrick S, de Groat WC, Birder LA. Heterogeneity of muscarinic receptor-mediated Ca2+ responses in cultured urothelial cells from rat. Am. J. Physiol. Renal Physiol. 2008; 294: F971-981.
24. Mukerji G, Yiangou Y, Grogono J etal. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J. Urol. 2006; 176: 367-373.
25. Birder LA, Barrick SR, Roppolo JR etal. Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. Am. J. Physiol. Renal Physiol. 2003; 285: F423-429.
26. Chen CC, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN. A P2X purinoceptor expressed by a subset of sensory neurons. Nature 1995; 377: 428-431.
27. Dunn PM, Zhong Y, Burnstock G. P2X receptors in peripheral neurons. Prog. Neurobiol. 2001; 65: 107-134.
28. Brading AF, Turner WH. The unstable bladder: towards a common mechanism. Br. J. Urol. 1994; 73: 3-8.
29. Brading AF. A myogenic basis for the overactive bladder. Urology 1997; 50: 57-67; discussion 68-73.
30. Mills IW, Greenland JE, McMurray G etal. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J. Urol. 2000; 163: 646-651.
31. Drake MJ, Harvey IJ, Gillespie JI, Van Duyl WA. Localized contractions in the normal human bladder and in urinary urgency. BJU Int. 2005; 95: 1002-1005.
32. Downie JW, Armour JA. Mechanoreceptor afferent activity compared with receptor field dimensions and pressure changes in feline urinary bladder. Can. J. Physiol. Pharmacol. 1992; 70: 1457-1467.
33. Gillespie JI. A developing view of the origins of urgency: the importance of animal models. BJU Int. 2005; 96 (Suppl 1): 22-28.
34. Coolsaet BL, Van Duyl WA, Van Os-Bossagh P, De Bakker HV. New concepts in relation to urge and detrusor activity. Neurourol. Urodyn. 1993; 12: 463-471.
35. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J. Urol. 2005; 174: 2032-2036.
36. Hedlund P, Streng T, Lee T, Andersson KE. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J. Urol. 2007; 178: 326-331.
37. Haga N, Aikawa K, Shishido K, Takahashi N, Yanagida T, Yamaguchi O. Effect of long-term oxybutynin administration on c-Fos expression in spinal neurons: inhibition of antimuscarinics on bladder afferents in conscious rats. Urology 2009; 73: 200-204.
38. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol. Urodyn. 2006; 25: 156-161.
39. Iijima K, De Wachter S, Wyndaele JJ. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur. Urol. 2007; 52: 842-847.
40. Bylund DB, Eikenberg DC, Hieble JP etal. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 1994; 46: 121-136.
41. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn. Schmiedebergs Arch. Pharmacol. 2004; 369: 151-159.
42. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharm. 2006; 147 (Suppl 2): S88-119.
43. Emorine LJ, Marullo S, Briend-Sutren MM etal. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989; 245: 1118-1121.
44. Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, Emorine LJ. Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J. 1991; 10: 3721-3727.
45. Granneman JG, Lahners KN, Chaudhry A. Molecular cloning and expression of the rat beta 3-adrenergic receptor. Mol. Pharmacol. 1991; 40: 895-899.
46. Fujimura T, Tamura K, Tsutsumi T etal. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J. Urol. 1999; 161: 680-685.
47. Matsubara S, Okada H, Shirakawa T, Gotoh A, Kuno T, Kamidono S. Estrogen levels influence beta-3-adrenoceptor-mediated relaxation of the female rat detrusor muscle. Urology 2002; 59: 621-625.
48. Seguchi H, Nishimura J, Zhou Y, Niiro N, Kumazawa J, Kanaide H. Expression of beta3-adrenoceptors in rat detrusor smooth muscle. J. Urol. 1998; 159: 2197-2201.
49. Igawa Y, Yamazaki Y, Takeda H etal. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br. J. Pharmacol. 1999; 126: 819-825.
50. Takeda M, Obara K, Mizusawa T etal. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther. 1999; 288: 1367-1373.
51. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J. Urol. 2003; 170: 649-653.
52. Morita T, Iizuka H, Iwata T, Kondo S. Function and distribution of beta3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter. J. Smooth Muscle Res. 2000; 36: 21-32.
53. Oshita M, Hiraoka Y, Watanabe Y. Characterization of beta-adrenoceptors in urinary bladder: comparison between rat and rabbit. Br. J. Pharmacol. 1997; 122: 1720-1724.
54. Yamazaki Y, Takeda H, Akahane M, Igawa Y, Nishizawa O, Ajisawa Y. Species differences in the distribution of beta-adrenoceptor subtypes in bladder smooth muscle. Br. J. Pharmacol. 1998; 124: 593-599.
55. Longhurst PA, Levendusky M. Pharmacological characterization of beta-adrenoceptors mediating relaxation of the rat urinary bladder in vitro. Br. J. Pharmacol. 1999; 127: 1744-1750.
56. Takeda H, Yamazaki Y, Akahane M, Igawa Y, Ajisawa Y, Nishizawa O. Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J. Pharmacol. Exp. Ther. 2000; 293: 939-945.
57. Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R. The role of beta(3)-adrenoceptors in mediating relaxation of porcine detrusor muscle. Br. J. Pharmacol. 2002; 135: 129-134.
58. Takeda H, Matsuzawa A, Igawa Y etal. Functional characterization of beta-adrenoceptor subtypes in the canine and rat lower urinary tract. J. Urol. 2003; 170: 654-658.
59. Igawa Y, Yamazaki Y, Takeda H etal. Possible beta 3-adrenoceptor-mediated relaxation of the human detrusor. Acta Physiol. Scand. 1998; 164: 117-118.
60. Kaidoh K, Igawa Y, Takeda H etal. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J. Urol. 2002; 168: 1247-1252.
61. Takeda H, Yamazaki Y, Igawa Y etal. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol. Urodyn. 2002; 21: 558-565.
62. Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM. Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J. Urol. 2001; 166: 1142-1147.
63. Hegde SS, Choppin A, Bonhaus D etal. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol. 1997; 120: 1409-1418.
64. Thomas C, Tyagi S, Masuda H. β-adrenocepter subtype 1, 2 and 3 mRNA are all present in human detrusor muscle and urothelium. J. Urol. 2005; 173: 45A.
65. Birder LA, Nealen ML, Kiss S etal. Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J. Neurosci. 2002; 22: 8063-8070.
66. Andersson KE, Persson K. Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Scand. J. Urol. Nephrol. 1995; 175: 43-53.
67. Pandita RK, Fujiwara M, Alm P, Andersson KE. Cystometric evaluation of bladder function in non-anesthetized mice with and without bladder outlet obstruction. J. Urol. 2000; 164: 1385-1389.
68. Yamaguchi O, Kakizaki H, Homma Y. A phase?, randomized, double-blind, placebo and active controlled study of once-dairy mirabegron 50mg in patients with overactive bladder. Urology 2012; 80 (Suppl 3A): S10-11.
69. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int. J. Urol. 2008; 15: 193-199.
70. Moriyama N, Kurimoto S, Horie S etal. Detection of alpha 1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization. Histochem. J. 1996; 28: 283-288.
71. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006; 98: 1019-1024.
72. Chen Q, Takahashi S, Zhong S etal. Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor. J. Urol. 2005; 174: 370-374.
73. Malloy BJ, Price DT, Price RR etal. Alpha1-adrenergic receptor subtypes in human detrusor. J. Urol. 1998; 160: 937-943.
74. Hampel C, Dolber PC, Smith MP etal. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J. Urol. 2002; 167: 1513-1521.
75. Bouchelouche K, Andersen L, Alvarez S, Nordling J, Bouchelouche P. Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrenergic receptor antagonist tamsulosin. J. Urol. 2005; 173: 657-661.
76. Smith MS, Schambra UB, Wilson KH, Page SO, Schwinn DA. Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels. Brain Res. Mol. Brain Res. 1999; 63: 254-261.
77. Ishihama H, Momota Y, Yanase H, Wang X, de Groat WC, Kawatani M. Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J. Urol. 2006; 175: 358-364.
78. Azadzoi KM, Pontari M, Vlachiotis J, Siroky MB. Canine bladder blood flow and oxygenation: changes induced by filling, contraction and outlet obstruction. J. Urol. 1996; 155: 1459-1465.
79. Greenland JE, Brading AF. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J. Urol. 2001; 165: 245-248.
80. Koritsiadis G, Stravodimos K, Koutalellis G etal. Immunohistochemical estimation of hypoxia in human obstructed bladder and correlation with clinical variables. BJU Int. 2008; 102: 328-332.
81. Mariappan P, Chong WL. Prevalence and correlations of lower urinary tract symptoms, erectile dysfunction and incontinence in men from a multiethnic Asian population: results of a regional population-based survey and comparison with industrialized nations. BJU Int. 2006; 98: 1264-1268.
82. Kaplan SA. Male pelvic health: a urological call to arms. J. Urol. 2006; 176: 2351-2352.
83. Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur. Urol. 2006; 50: 581-586.
84. Azadzoi KM, Tarcan T, Kozlowski R, Krane RJ, Siroky MB. Overactivity and structural changes in the chronically ischemic bladder. J. Urol. 1999; 162: 1768-1778.
85. Shenfeld OZ, Meir KS, Yutkin V, Gofrit ON, Landau EH, Pode D. Do atherosclerosis and chronic bladder ischemia really play a role in detrusor dysfunction of old age? Urology 2005; 65: 181-184.
86. Nomiya M, Yamaguchi O, Andersson KE etal. The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat. Neurourol. Urodyn. 2012; 31: 195-200.
87. Masuda H, Kihara K, Saito K etal. Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int. 2008; 101: 775-780.
88. Pinggera GM, Mitterberger M, Pallwein L etal. alpha-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int. 2008; 101: 319-324.
89. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003; 92: 257-261.
90. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J. Urol. 1998; 160: 1701-1706.
91. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892-900.
92. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). The European Tamsulosin Study Group. Br. J. Urol. 1995; 76: 325-336.
93. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004; 94: 817-820.
94. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296: 2319-2328.
95. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur. Urol. 2009; 56: 534-541.
96. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J. Urol. 2009; 182: 2825-2830.
97. MacDiarmid SA, Peters KM, Chen A etal. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin. Proc. 2008; 83: 1002-1010.
98. Nishizawa O, Yamaguchi O, Takeda M. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. LUTS 2011; 3: 29-35.
99. Yamaguchi O, Kakizaki H, Homma Y etal. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study. Urology 2011; 78: 126-133.
100. Gormley GJ, Stoner E, Bruskewitz RC etal. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. 1992; 327: 1185-1191.
101. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405.
102. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997; 49: 839-845.
103. McConnell JD, Bruskewitz R, Walsh P etal. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl. J. Med. 1998; 338: 557-563.
104. Roehrborn CG, Bruskewitz R, Nickel GC etal. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur. Urol. 2000; 37: 528-536.
105. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Hofner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003; 92: 262-266.
106. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur. Urol. 2004; 46: 488-494; discussion 495.
107. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-441.
108. Lepor H, Williford WO, Barry MJ etal. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Engl. J. Med. 1996; 335: 533-539.
109. Debruyne FM, Jardin A, Colloi D etal. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur. Urol. 1998; 34: 169-175.
110. Kirby RS, Roehrborn C, Boyle P etal. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-126.
111. McConnell JD, Roehrborn CG, Bautista OM etal. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349: 2387-2398.
112. Becher E, Roehrborn CG, Siami P, Gagnier RP, Wilson TH, Montorsi F. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis. 2009; 12: 369-374.
113. Roehrborn CG, Siami P, Barkin J etal. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57: 123-131.
114. Rosen R, Altwein J, Boyle P etal. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 2003; 44: 637-649.
115. Ponholzer A, Temml C, Obermayr R, Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004; 64: 772-776.
116. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur. Urol. 2005; 47: 838-845.
117. El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: is there a vascular association? Eur. Urol. 2005; 48: 319-325.
118. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur. Urol. 2005; 47: 824-837.
119. Hoesl CE, Woll EM, Burkart M, Altwein JE. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur. Urol. 2005; 47: 511-517.
120. Truss MC, Stief CG, Uckert S etal. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J. Urol. 2001; 19: 344-350.
121. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J. Urol. 2001; 166: 2484-2490.
122. Gillespie JI, Markerink-van Ittersum M, De Vente J. Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: evidence for distinct populations of sub-urothelial interstitial cells. Cell Tissue Res. 2006; 325: 325-332.
123. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J. Urol. 2007; 177: 1071-1077.
124. McVary KT, Roehrborn CG, Kaminetsky JC etal. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2007; 177: 1401-1407.
125. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J. Urol. 2008; 180: 1228-1234.
126. Porst H, McVary KT, Montorsi F etal. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur. Urol. 2009; 56: 727-735.
127. Takeda H, Nishizawa O, Imaoka T, Morisaki Y, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12-week placebo-controlled dose-finding study with a 42-week open-label extension. LUTS 2012; 4: 110-119.
128. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur. Urol. 2007; 51: 1717-1723.